A New Era: CRISPR Meets NRF2
In one of the most exciting developments in NRF2 research, scientists at ChristianaCare's Gene Editing Institute have demonstrated that CRISPR-Cas9 gene editing can selectively disable cancer-driving NRF2 mutations, restoring chemotherapy sensitivity in lung cancer models — without affecting healthy cells.
The Breakthrough
Published in Molecular Therapy Oncology in November 2025, the study by Kelly Banas and Eric Kmiec exploited a clever biological trick:
- Many lung squamous cell carcinomas carry an NRF2 R34G mutation that makes tumors resistant to chemotherapy
- This specific mutation creates a unique PAM site — the DNA sequence CRISPR-Cas9 needs to cut
- Because normal cells don't have this mutation, the CRISPR system can selectively target only tumor cells
- Even modest editing (20-40%) of tumor cells was sufficient to restore sensitivity to standard carboplatin-paclitaxel chemotherapy
Expanding Beyond Lung Cancer
In January 2026, the same team extended their approach to head and neck cancers and esophageal cancer, targeting NRF2 exon 4 and achieving a remarkable 90% reduction in NRF2 protein levels. This demonstrates the approach's broad applicability across solid tumors with NRF2 aberrations.
Clinical Translation
The therapy uses lipid nanoparticle delivery with minimal off-target effects. CorriXR Therapeutics, a spinout company, is pursuing IND-enabling studies with the goal of becoming the first CRISPR therapy targeting NRF2 in cancer to reach clinical trials.
Why This Matters
This approach elegantly resolves the NRF2 duality problem in cancer — instead of systemic NRF2 modulation that could harm normal cells, CRISPR enables tumor-specific editing. It could allow patients to respond to standard chemotherapy again, potentially at lower doses with fewer side effects.